OPIG recently celebrated its 20th year; and on 10 January 2023 I gave a talk just a day before the 10th anniversary of BLOPIG’s first blog post. It’s worth reflecting on what’s stayed the same and what’s changed since then.
Continue readingTag Archives: Fragment-Based Drug Discovery
Viewing fragment elaborations in RDKit
As a reasonably new RDKit user, I was relieved to find that using its built-in functionality for generating basic images from molecules is quite easy to use. However, over time I have picked up some additional tricks to make the images generated slightly more pleasing on the eye!
The first of these (which I definitely stole from another blog post at some point…) is to ask it to produce SVG images rather than png:
#ensure the molecule visualisation uses svg rather than png format IPythonConsole.ipython_useSVG=True
Now for something slightly more interesting: as a fragment elaborator, I often need to look at a long list of elaborations that have been made to a starting fragment. As these have usually been docked, these don’t look particularly nice when loaded straight into RDKit and drawn:
#load several mols from a single sdf file using SDMolSupplier
#add these to a list
elabs = [mol for mol in Chem.SDMolSupplier('frag2/elabsTestNoRefine_Docked_0.sdf')]
#get list of ligand efficiencies so these can be displayed alongside the molecules
LEs = [(float(mol.GetProp('Gold.PLP.Fitness'))/mol.GetNumHeavyAtoms()) for mol in elabs]
Draw.MolsToGridImage(elabs, legends = [str(LE) for LE in LEs])
Two quick changes that will immediately make this image more useful are aligning the elaborations by a supplied substructure (here I supplied the original fragment so that it’s always in the same place) and calculating the 2D coordinates of the molecules so we don’t see the twisty business happening in the bottom right of Fig. 1:
Continue readingFragment Based Drug Discovery with Crystallographic Fragment Screening at XChem and Beyond
Disclaimer: I’m a current PhD student working on PanDDA 2 for Frank von Delft and Charlotte Deane, and sponsored by Global Phasing, and some of this is my opinion – if it isn’t obvious in one of the references I probably said it so take it with a pinch of salt
Fragment Based Drug Discovery
Principle
Fragment based drugs discovery (FBDD) is a technique for finding lead compounds for medicinal chemistry. In FBDD a protein target of interest is identified for inhibition and a small library, typically of a few hundred compounds, is screened against it. Though these typically bind weakly, they can be used as a starting point for chemical elaboration towards something more lead-like. This approach is primarily contrasted with high throughput screening (HTS), in which an enormous number of larger, more complex molecules are screened in order to find ones which bind. The key idea is recognizing that the molecules in these HTS libraries can typically be broken down into a much smaller number of common substructures, fragments, so screening these ought to be more informative: between them they describe more of the “chemical space” which interacts with the protein. Since it first appeared about 25 years ago, FBDD has delivered four drugs for clinical use and over 40 molecules to clinical trials.
Continue reading